It was hard to miss the headlines out of the recent American College of Cardiology meeting in Chicago: Vytorin, the blockbuster cholesterol drug combination from Merck and Schering-Plough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback